Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Hepion Pharmaceuticals (NASDAQ: HEPA) Reports Promising Phase 2 Trial Results for NASH Treatment Spotlight Growth - Mon May 22, 2023

Renocofilstat's Positive Outcomes Reinforce Antifibrotic Action Hepion Pharmaceuticals, a clinical stage biopharmaceutical company focusing on AI-assisted therapeutic drug development, recently

HEPA : 1.4600 (-3.95%)
Wall Street - shutterstock_93231562
Pre-Market Brief: Stocks Mostly Higher As Investors Await U.S. Inflation Data Barchart - Wed Jan 11, 2023

March S&P 500 futures (ESH23) are trending up +0.32% this morning after three major U.S. benchmark indices finished the regular session higher as market participants awaited U.S. inflation data for further...

ESH23 : 3,957.05s (-0.09%)
JD-.LN : 115.700 (+1.62%)
HEPA : 1.4600 (-3.95%)
BWEN : 2.23 (+3.72%)
PROK : 2.20 (+2.33%)
CONN : 3.35 (-3.74%)
SHC : 11.02 (+1.01%)
STM : 40.07 (+2.27%)
Hepion Pharmaceuticals Announces Further Adjournment of Annual Meeting of Stockholders Globe Newswire - Fri Jul 22, 2022

EDISON, N.J., July 22, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4600 (-3.95%)
Hepion Pharmaceuticals Further Strengthens Board with Appointments of Accomplished Biopharmaceutical Executives, Mr. Anand Reddi and Dr. Kaouthar Lbiati Globe Newswire - Tue Jun 28, 2022

EDISON, N.J., June 28, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4600 (-3.95%)
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Globe Newswire - Fri Jun 24, 2022

EDISON, N.J., June 24, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4600 (-3.95%)
Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for Rencofilstat for the Treatment of Hepatocellular Carcinoma Globe Newswire - Mon Jun 20, 2022

EDISON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical mid-stage biopharmaceutical company focused on...

HEPA : 1.4600 (-3.95%)
Hepion Pharmaceuticals to Present Five Posters at EASL International Liver Congress™ 2022 Globe Newswire - Wed Jun 15, 2022

- Hepion Represented as Authors in Preclinical and Clinical Posters Related to Rencofilstat and Cyclophilins – EDISON, N.J., June 15, 2022 (GLOBE...

HEPA : 1.4600 (-3.95%)
Hepion Pharmaceuticals Urges Shareholders to Vote “FOR” All Proposals Ahead of its Upcoming Annual Meeting Globe Newswire - Tue May 31, 2022

EDISON, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...

HEPA : 1.4600 (-3.95%)
CORRECTING and REPLACING - Hepion Pharmaceuticals, Inc. Globe Newswire - Fri May 27, 2022

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we've been...

HEPA : 1.4600 (-3.95%)
Hepion Pharmaceuticals Highlights Upcoming Phase 2 Clinical Trials of Recofilstat at 5th Global NASH Congress Globe Newswire - Fri May 27, 2022

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on...

HEPA : 1.4600 (-3.95%)

Barchart Exclusives

5 Stocks to Buy on Surging AI Data Center Demand Barchart - 57 minutes ago
Financial services giant Goldman Sachs remains bullish on AI data center demand. Here are five stocks they like to play the investing megatrend. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot